VCMCVC Market Cap
Menu

Medable valuation, funding and investors

medable.com ↗LinkedIn ↗

Medable works in decentralized clinical trial platform development, based in Palo Alto, United States. Founded in 2015, it has about 329 employees.

Tech Companies Palo Alto Series D
VALUATION · TODAY
$1.12B −5% after Series D
Range $158M – $2.55B · Grade D
TODAY
+12 MO
$1.00B
$2.00B
$3.00B
$4.00B
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Series A
Growth $25.0M
Series C $91.0M
Growth $78.0M
Series D $304M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY344 employees
+0%6m growth
+5%1y growth
−9%2y growth
250
500
750
Data from Jan 2021
TODAY
Predicted in 1 yr $1.07B −5% vs today
Predicted next raise $271M if a round comes
Winding-down probability 36%
Last round
Series D · $304M · Oct 2021
Valuation at last round
$2.10B
Headcount
344 · flat
Grade
D
Founded
2015
How VCMC values companies →

Medable valuation today

VCMC values Medable at $1.1B today, with a range of $158M to $2.6B and a grade of D. The valuation starts from its last funding round, a Series D round in Oct 2021.

Valuation by date (148 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Medable: valuation by date, as the model would have shown it on each date
DateValuationRangePredicted in 1 yrPhaseHeadcountTrendGradeWinding-down probability
1 Jan 2015$5.17M$1.88M – $14.2M$5.41M (+5%)before first round–unknownD0%
1 Feb 2015$5.19M$1.89M – $14.2M$5.44M (+5%)before first round–unknownD0%
1 Mar 2015$5.21M$1.90M – $14.3M$5.46M (+5%)before first round–unknownD0%
1 Apr 2015$5.23M$1.90M – $14.4M$5.48M (+5%)before first round–unknownD0%
1 May 2015$5.25M$1.91M – $14.4M$5.50M (+5%)before first round–unknownD0%
1 Jun 2015$5.27M$1.92M – $14.5M$5.52M (+5%)before first round–unknownD0%
1 Jul 2015$5.29M$1.93M – $14.5M$5.54M (+5%)before first round–unknownD0%
1 Aug 2015$5.31M$1.93M – $14.6M$5.69M (+7%)before first round–unknownD0%
1 Sep 2015$5.33M$1.94M – $14.6M$5.84M (+10%)before first round–unknownD0%
1 Oct 2015$5.35M$1.95M – $14.7M$5.99M (+12%)before first round–unknownD0%
1 Nov 2015$5.37M$1.96M – $14.8M$6.16M (+15%)before first round–unknownD0%
1 Dec 2015$5.39M$1.96M – $14.8M$6.32M (+17%)before first round–unknownD0%
1 Jan 2016$5.41M$1.97M – $14.9M$6.49M (+20%)before first round–unknownD0%
1 Feb 2016$5.44M$1.98M – $14.9M$6.67M (+23%)before first round–unknownD0%
1 Mar 2016$5.46M$1.99M – $15.0M$6.84M (+25%)before first round–unknownD0%
1 Apr 2016$5.48M$1.99M – $15.0M$7.02M (+28%)before first round–unknownD0%
1 May 2016$5.50M$2.00M – $15.1M$7.21M (+31%)before first round–unknownD0%
1 Jun 2016$5.52M$2.01M – $15.2M$7.40M (+34%)before first round–unknownD0%
1 Jul 2016$5.54M$2.02M – $15.2M$7.60M (+37%)before first round–unknownD0%
16 Jul 2016$60.1M$30.1M – $215M$108M (+80%)after a round–unknownC0%
1 Aug 2016$61.7M$30.1M – $215M$108M (+75%)after a round–unknownC0%
1 Sep 2016$64.8M$30.1M – $215M$108M (+67%)after a round–unknownC0%
1 Oct 2016$68.0M$30.1M – $215M$108M (+59%)after a round–unknownC0%
1 Nov 2016$71.5M$30.1M – $215M$108M (+51%)after a round–unknownC0%
1 Dec 2016$75.0M$30.1M – $215M$108M (+44%)after a round–unknownC0%
1 Jan 2017$78.9M$30.1M – $215M$108M (+37%)after a round–unknownC0%
1 Feb 2017$82.9M$30.1M – $215M$108M (+30%)after a round–unknownC0%
1 Mar 2017$86.7M$30.1M – $215M$108M (+25%)after a round–unknownC0%
1 Apr 2017$91.2M$30.1M – $215M$108M (+18%)after a round–unknownC0%
1 May 2017$95.7M$30.1M – $215M$108M (+13%)after a round–unknownC0%
1 Jun 2017$101M$30.1M – $215M$108M (+7%)after a round–unknownC0%
1 Jul 2017$106M$30.1M – $215M$108M (+2%)after a round–unknownC0%
1 Aug 2017$108M$29.3M – $215M$108M (0%)after a round–unknownC0%
1 Sep 2017$108M$27.8M – $215M$108M (0%)after a round–unknownD0%
1 Oct 2017$108M$26.5M – $215M$108M (0%)after a round–unknownD0%
1 Nov 2017$108M$25.2M – $215M$108M (0%)after a round–unknownD0%
1 Dec 2017$108M$24.0M – $215M$108M (0%)after a round–unknownD0%
1 Jan 2018$108M$22.8M – $215M$108M (0%)after a round–unknownD0%
1 Feb 2018$108M$21.6M – $215M$108M (0%)after a round–unknownD0%
1 Mar 2018$108M$20.7M – $215M$108M (0%)after a round–unknownD0%
1 Apr 2018$108M$19.6M – $215M$108M (0%)after a round–unknownD0%
1 May 2018$108M$18.7M – $215M$108M (0%)after a round–unknownD0%
1 Jun 2018$108M$17.8M – $215M$108M (0%)after a round–unknownD0%
1 Jul 2018$108M$16.9M – $215M$108M (0%)after a round–unknownD0%
1 Aug 2018$108M$16.1M – $215M$108M (0%)after a round–unknownD0%
1 Sep 2018$108M$15.3M – $215M$108M (0%)after a round–unknownD0%
1 Oct 2018$108M$14.5M – $215M$108M (0%)after a round–unknownD0%
1 Nov 2018$108M$13.8M – $215M$108M (0%)after a round–unknownD0%
1 Dec 2018$108M$13.2M – $215M$108M (0%)after a round–unknownD0%
1 Jan 2019$108M$12.5M – $215M$108M (0%)after a round–unknownD0%
1 Feb 2019$108M$11.9M – $215M$108M (0%)after a round–unknownD0%
1 Mar 2019$108M$11.3M – $215M$108M (0%)after a round–unknownD0%
1 Apr 2019$108M$10.8M – $215M$108M (0%)after a round–unknownD0%
1 May 2019$108M$10.3M – $215M$108M (0%)after a round–unknownD0%
1 Jun 2019$108M$9.76M – $215M$108M (0%)after a round–unknownD0%
1 Jul 2019$108M$9.29M – $215M$108M (0%)after a round–unknownD0%
1 Aug 2019$108M$8.83M – $215M$108M (0%)after a round–unknownD0%
1 Sep 2019$108M$8.39M – $215M$108M (0%)after a round–unknownD0%
1 Oct 2019$108M$7.98M – $215M$108M (0%)after a round–unknownD0%
1 Nov 2019$108M$7.59M – $215M$108M (0%)after a round–unknownD0%
1 Dec 2019$108M$7.22M – $215M$108M (0%)after a round–unknownD0%
1 Jan 2020$108M$6.86M – $215M$108M (0%)after a round–unknownD0%
1 Feb 2020$108M$6.52M – $215M$108M (0%)after a round–unknownD0%
1 Mar 2020$108M$6.22M – $215M$108M (0%)after a round–unknownD0%
1 Apr 2020$108M$5.91M – $215M$108M (0%)after a round–unknownD0%
1 May 2020$108M$5.63M – $215M$108M (0%)after a round–unknownD0%
5 May 2020$278M$183M – $465M$306M (+10%)after a round–unknownB0%
1 Jun 2020$280M$183M – $465M$306M (+9%)after a round–unknownB0%
1 Jul 2020$282M$183M – $465M$306M (+8%)after a round–unknownB0%
1 Aug 2020$284M$183M – $465M$306M (+7%)after a round–unknownB0%
1 Sep 2020$287M$183M – $465M$306M (+7%)after a round–unknownB0%
1 Oct 2020$289M$183M – $465M$306M (+6%)after a round–unknownB0%
1 Nov 2020$291M$183M – $465M$306M (+5%)after a round–unknownB0%
20 Nov 2020$608M$428M – $1.1B$790M (+30%)after a round–unknownB0%
1 Dec 2020$613M$428M – $1.1B$790M (+29%)after a round–unknownB0%
1 Jan 2021$626M$428M – $1.1B$790M (+26%)after a round140unknownB0%
1 Feb 2021$641M$428M – $1.1B$790M (+23%)after a round140unknownB0%
1 Mar 2021$654M$428M – $1.1B$790M (+21%)after a round140unknownB0%
1 Apr 2021$668M$428M – $1.1B$790M (+18%)after a round140flatB0%
21 Apr 2021$805M$567M – $1.3B$885M (+10%)after a round140flatB0%
1 May 2021$807M$567M – $1.3B$885M (+10%)after a round140flatB0%
1 Jun 2021$813M$567M – $1.3B$885M (+9%)after a round140flatB0%
1 Jul 2021$820M$567M – $1.3B$885M (+8%)after a round140flatB0%
1 Aug 2021$826M$567M – $1.3B$885M (+7%)after a round140flatB0%
1 Sep 2021$833M$567M – $1.3B$885M (+6%)after a round140flatB0%
1 Oct 2021$840M$567M – $1.3B$885M (+5%)after a round140flatB0%
28 Oct 2021$2.1B$1.8B – $3.1B$2.7B (+30%)after a round140flatA0%
1 Nov 2021$2.1B$1.8B – $3.1B$2.7B (+30%)after a round140flatA0%
1 Dec 2021$2.2B$1.8B – $3.1B$2.7B (+27%)after a round140flatA0%
1 Jan 2022$2.2B$1.8B – $3.1B$2.7B (+24%)after a round140flatA0%
1 Feb 2022$2.3B$1.8B – $3.1B$2.7B (+21%)after a round140flatA0%
1 Mar 2022$2.3B$1.8B – $3.1B$2.7B (+19%)after a round550growingA0%
1 Apr 2022$2.3B$1.8B – $3.1B$2.7B (+16%)after a round550growingA0%
1 May 2022$2.4B$1.8B – $3.1B$2.7B (+14%)after a round550growingA0%
1 Jun 2022$2.5B$1.8B – $3.1B$2.7B (+11%)after a round550growingA0%
1 Jul 2022$2.5B$1.8B – $3.1B$2.7B (+9%)after a round550growingA0%
1 Aug 2022$2.6B$1.8B – $3.1B$2.7B (+6%)after a round550growingA0%
1 Sep 2022$2.6B$1.8B – $3.1B$2.7B (+4%)after a round550growingA0%
1 Oct 2022$2.7B$1.8B – $3.1B$2.7B (+2%)after a round550growingA0%
1 Nov 2022$2.7B$1.8B – $3.1B$2.7B (0%)after a round550unknownA0%
1 Dec 2022$2.7B$1.7B – $3.1B$2.7B (0%)after a round550unknownA0%
1 Jan 2023$2.8B$1.8B – $3.2B$2.8B (0%)after a round620upA0%
1 Feb 2023$2.8B$1.8B – $3.2B$2.8B (0%)after a round620upA0%
1 Mar 2023$2.8B$1.8B – $3.2B$2.8B (0%)after a round620upB0%
1 Apr 2023$2.8B$1.7B – $3.2B$2.8B (0%)after a round620upB0%
1 May 2023$2.8B$1.7B – $3.2B$2.8B (0%)after a round620upB0%
1 Jun 2023$2.8B$1.7B – $3.2B$2.8B (0%)after a round620upB0%
1 Jul 2023$2.8B$1.7B – $3.2B$2.8B (0%)after a round620upB0%
1 Aug 2023$2.8B$1.7B – $3.2B$2.8B (0%)after a round620upB0%
1 Sep 2023$2.8B$1.7B – $3.2B$2.8B (0%)after a round620upB0%
1 Oct 2023$1.6B$1.0B – $2.7B$1.2B (-28%)after a round490downB97%
1 Nov 2023$1.5B$970M – $2.7B$1.0B (-33%)after a round490downB97%
1 Dec 2023$1.5B$923M – $2.7B$1.0B (-33%)after a round490downB97%
1 Jan 2024$1.5B$877M – $2.8B$971M (-34%)after a round490downB97%
1 Feb 2024$1.2B$814M – $2.1B$684M (-41%)after a round440shrinkingB97%
1 Mar 2024$1.1B$772M – $2.1B$654M (-41%)after a round430shrinkingB97%
1 Apr 2024$1.1B$734M – $2.1B$627M (-41%)after a round430shrinkingB97%
1 May 2024$1.0B$699M – $2.1B$602M (-41%)after a round430shrinkingB97%
1 Jun 2024$989M$664M – $2.1B$577M (-42%)after a round430shrinkingB97%
1 Jul 2024$954M$632M – $2.1B$554M (-42%)after a round430shrinkingB97%
1 Aug 2024$1.2B$585M – $2.8B$733M (-37%)after a round380downC97%
1 Sep 2024$1.1B$556M – $2.8B$709M (-38%)after a round380downC97%
1 Oct 2024$1.1B$529M – $2.9B$687M (-38%)after a round380downC97%
1 Nov 2024$741M$497M – $1.6B$431M (-42%)after a round360shrinkingB97%
1 Dec 2024$712M$473M – $1.5B$414M (-42%)after a round360shrinkingB97%
1 Jan 2025$682M$449M – $1.5B$396M (-42%)after a round360shrinkingC97%
1 Feb 2025$654M$427M – $1.5B$379M (-42%)after a round360shrinkingC97%
1 Mar 2025$630M$408M – $1.4B$365M (-42%)after a round360shrinkingC97%
1 Apr 2025$604M$388M – $1.4B$349M (-42%)after a round360shrinkingC97%
1 May 2025$798M$369M – $2.9B$497M (-38%)after a round360downD97%
1 Jun 2025$773M$351M – $2.9B$480M (-38%)after a round360downD97%
1 Jul 2025$748M$334M – $2.9B$464M (-38%)after a round360downD97%
1 Aug 2025$708M$310M – $2.8B$439M (-38%)after a round326downD97%
1 Sep 2025$686M$295M – $2.8B$425M (-38%)after a round327downD97%
1 Oct 2025$732M$281M – $2.8B$481M (-34%)after a round327downD89%
1 Nov 2025$730M$267M – $2.8B$540M (-26%)after a round329downD82%
1 Dec 2025$767M$254M – $2.7B$590M (-23%)after a round329downD76%
1 Jan 2026$745M$242M – $2.7B$589M (-21%)after a round329downD76%
1 Feb 2026$723M$230M – $2.7B$588M (-19%)after a round329downD76%
1 Mar 2026$770M$219M – $2.7B$646M (-16%)after a round329flatD70%
1 Apr 2026$822M$211M – $2.7B$709M (-14%)after a round344flatD65%
1 May 2026$866M$201M – $2.7B$766M (-12%)after a round344flatD59%
1 Jun 2026$921M$191M – $2.7B$839M (-9%)after a round344flatD55%
1 Jul 2026$966M$181M – $2.6B$896M (-7%)after a round344flatD50%
1 Aug 2026$1.0B$172M – $2.6B$951M (-6%)after a round344flatD46%
1 Sep 2026$1.1B$165M – $2.6B$1.0B (-5%)after a round344flatD43%
1 Oct 2026$1.1B$165M – $2.6B$1.1B (-5%)after a round344flatD39%
24 Oct 2026$1.1B$158M – $2.6B$1.1B (-5%)after a round344flatD36%

Key facts about Medable

Founded
2015
Headquarters
Palo Alto, United States
Employees
about 329 -9% in a year
Total raised
$498M
Funding rounds
5
Last round
Series D Oct 2021

Medable was founded in 2015 by Fernando Waigandt, James Sas, Michelle Longmire, Perry Robinson and Tim Smith.

Medable funding history

Medable has 5 funding rounds on record, from Jul 2016 to Oct 2021, $498M in total. The latest disclosed valuation is $2.10B post-money (Series D, Oct 2021).

  1. Series D 27 Oct 2021

    Led by Blackstone, Tiger Global; with GSR Ventures, Sapphire Ventures, Western Technology Investment.

    Sources: finsmes.com, businesswire.com

    $304M

    $2.10B post-money

  2. Growth Equity 20 Apr 2021

    Led by Sapphire Ventures; with Obvious, GSR Ventures, Pharmaceutical Product Development, Streamlined Ventures.

    Sources: stockanalysis.com, fiercebiotech.com

    $78M

  3. Series C 19 Nov 2020

    Led by Sapphire Ventures; with GSR Ventures, PPD, Inc. (Nasdaq:PPD), Streamlined Ventures, ACVC Partners.

    Sources: finsmes.com, mobihealthnews.com, fiercebiotech.com

    $91M

  4. Growth Equity 4 May 2020

    Led by GSR Ventures; with PPD, Inc..

    Sources: businesswire.com, mobihealthnews.com, finsmes.com and 1 more

    $25M

  5. Series A 15 Jul 2016

    With Launchpad Digital Health.

    Sources: prnewswire.com, finsmes.com

    Amount undisclosed

Medable investors

12 investors have backed Medable; GSR Ventures, Sapphire Ventures and Blackstone and 1 more led at least one round.

  • GSR Ventures lead, 4 rounds
  • Sapphire Ventures lead, 3 rounds
  • Blackstone lead
  • Tiger Global lead
  • Launchpad Digital Health
  • Pharmaceutical Product Development
  • PPD, Inc.
  • PPD, Inc. (Nasdaq:PPD)

What Medable does

Medable works in tech companies, with 15 recorded offerings and customers in healthcare and pharmaceuticals.

Medable Inc. is an American software company engaged in providing decentralized clinical trial solutions, including electronic clinical outcome assessment (eCOA), electronic consent (eConsent), remote monitoring, and connected sensor technologies. The company offers a cloud-based platform that supports clinical trials across various therapeutic areas, such as oncology, vaccine, cardiology, dermatology, endocrinology, and immunology, and serves clients in over 60 countries and 120 languages. Medable also collaborates with retail pharmacies, site networks, data providers, and direct-to-patient partners to support its clinical trial solutions.

Description from Veridion's company data.

Products and services

  • Decentralized Clinical Trial Platform Development
  • Electronic Consent Form Solutions
  • Electronic Clinical Outcome Assessment Solutions
  • Remote Patient Monitoring Solutions
  • Connected Sensor Data Integration
  • Therapeutic Area-Specific Solution Development
  • Clinical Trial Workflow Automation Solutions
  • Clinical Data Quality Enhancement Solutions
  • Cloud-agnostic Clinical Trial Platform Deployment
  • Multilingual Clinical Trial Platform Deployment
  • Clinical Trial Platform Integration Services
  • Clinical Research Technology Innovation
  • Direct-to-Patient Clinical Trial Access Solutions
  • Site Network Integration Services
  • Data Provider Integration Services

Markets

  • Healthcare
  • Pharmaceuticals

Technology

  • Decentralized Clinical Trial Technology
  • Cloud Computing
  • Connected Sensors for Remote Monitoring
  • Electronic Consent Forms
  • Electronic Clinical Outcome Assessment

Business model

  • Business-to-Business
  • Software-as-a-Service

Industry codes (NAICS)

  • 513210 Software Publishers 100% match

Questions about Medable

What is Medable worth?

Valuation $1.1B (range $158M to $2.6B), as of 24 Oct 2026. The last disclosed valuation was $2.10B (Series D, Oct 2021).

Has Medable raised money?

Medable has 5 funding rounds on record, from Jul 2016 to Oct 2021, $498M in total. The latest disclosed valuation is $2.10B post-money (Series D, Oct 2021).

Who has invested in Medable?

GSR Ventures, Sapphire Ventures, Blackstone, Tiger Global, Streamlined Ventures and ACVC Partners, and 6 more. Lead investors include GSR Ventures, Sapphire Ventures, Blackstone and Tiger Global.

How many people work at Medable?

About 329, down 9% over the last year. Headcount rose from 140 in Jan 2021 to 620 in Jan 2023, then fell to 344 in Apr 2026.

What does Medable do?

Medable works in tech companies, with 15 recorded offerings and customers in healthcare and pharmaceuticals. Its main offerings are decentralized clinical trial platform development, electronic consent form solutions and electronic clinical outcome assessment solutions.

When was Medable founded, and where is it based?

Medable was founded in 2015 and is based in Palo Alto, United States. It has about 329 employees, down 9% over the last year.

How we value companiesReport an issue